Ken Takeshita

No open positions remaining

Health Technology

News on Ken Takeshita

ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer	17/07	BU
Daiichi Sankyo : ASCO highlight briefing session materialPDF Live & On-demand Streaming	02/06	PU
AstraZeneca says Enhertu slashes disease progression risk in cancer	02/06	AN
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial	02/06	BU
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer	01/06	BU
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial	31/05	BU
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO	23/05	BU
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial	07/05	BU
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer	21/04	BU
Daiichi Sankyo - ENHERTU Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer	04/03	AQ
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial	03/03	BU
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy	28/02	BU
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	31/01	BU
Daiichi Sankyo Company, Limited, Q3 2025 Earnings Call, Jan 31, 2025	31/01
AstraZeneca and Daiichi Sankyo cheer priority US review of cancer drug	13/01	AN
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	13/01	BU
Daiichi Sankyo Company, Limited - Special Call	17/12
Daiichi Sankyo : Presentation materialPDF	16/12	PU
AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation	09/12	AN
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	09/12	BU
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis	06/12	BU
Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH	02/12	BU
Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor	25/11	AQ
AstraZeneca - Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer	13/11	AQ
Daiichi Sankyo - Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	13/11	AQ
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	12/11	BU
AstraZeneca - ENHERTU granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy	02/24/02	AQ
AstraZeneca and Daiichi hail Enhertu priority review in US	01/24/01	AN
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy	01/24/01	BU
Daiichi Sankyo - Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial	24/24/24	AQ
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial	23/24/23	BU
Daiichi Sankyo - Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer	18/24/18	AQ
Daiichi Sankyo Company, Limited Presents at WCLC/ESMO 2024, Sep-17-2024 08:00 AM	17/24/17
Daiichi Sankyo : WCLC/ESMO highlight briefing session materialPDF	17/24/17	PU
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors	15/24/15	BU
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial	09/24/09	BU
Astrazeneca - Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial	09/24/09	AQ
Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial	08/24/08	BU
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO	04/24/04	BU
Daiichi Sankyo - ENHERTU Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy	19/24/19	AQ
AstraZeneca and Daiichi Sankyo gets US and European nods for Enhertu	19/24/19	AN
ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy	19/24/19	BU
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer	19/24/19	BU
Daiichi Sankyo and Merck & Co., Inc., Rahway, NJ, USA Enter into Global Development and Commercialization Agreement for MK-6070	07/24/07	AQ
Merck - Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	27/24/27	AQ
Daiichi Sankyo Company, Limited - Special Call	04/24/04
Daiichi Sankyo : ASCO highlight briefing session materia	03/24/03	PU
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy	02/24/02	BU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	28/24/28	AQ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	27/24/27	MT

Linked companies

Listed companies	1
DAIICHI SANKYO COMPANY, LIMITED	Health Technology

Private companies	1
Kite Pharma, Inc. Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on June 1, 2009 and is headquartered in Santa Monica, CA.	Health Technology

Private companies

Health Technology